Journal
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume 25, Issue 1, Pages 95-99Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.euroneuro.2014.11.019
Keywords
Transgender; Estradiol; Testosterone; Neurotrophin; Gender identity disorder; Gender dysphoria
Funding
- Bayer
Ask authors/readers for more resources
Serum levels of brain-derived neurotrophic factor (BDNF) are reduced in male-to-female transsexual persons (MtF) compared to male controls. It was hypothesized before that this might reflect either an involvement of BDNF in a biomechanism of transsexualism or to be the result of persistent social stress due to the condition. Here, we demonstrate that 12 month of cross-sex hormone treatment reduces serum BDNF levels in male-to-female transsexual persons independent of anthropometric measures. Participants were acquired through the European Network for the Investigation of Gender Incongruence (ENIGI). Reduced serum BDNF in MtF thus seems to be a result of hormonal treatment rather than a consequence or risk factor of transsexualism. (C) 2014 Elsevier B.V. and ECNP. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available